A naturally occurring copper-binding tripeptide with well-documented roles in wound healing, skin remodeling, and anti-aging biology.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →GHK-Cu — copper peptide GHK — is a naturally occurring tripeptide-copper complex consisting of the three amino acids glycine, histidine, and lysine (Gly-His-Lys) chelated with a copper(II) ion. It is among the most extensively studied copper-binding peptides in human biology, and its story begins with one of the more serendipitous discoveries in modern biochemistry. In 1973, Dr. Loren Pickart, then a graduate student at the University of California San Francisco, was investigating why old human plasma failed to support normal protein synthesis in liver tissue explants the way young plasma did. In a process of systematic fractionation, he isolated the fraction responsible and identified it as a tripeptide — Gly-His-Lys — which was abundant in young plasma and present at lower levels in older plasma. The peptide turned out to be a natural fragment of human albumin, the dominant plasma protein, released during albumin degradation in tissues.
Pickart continued researching this compound for decades, ultimately establishing GHK-Cu as a biologically active copper carrier with potent effects on wound healing, skin biology, and — in later work using genomic tools — a remarkably broad influence on gene expression. The peptide has a molecular weight of approximately 340 Da (as the free tripeptide) or around 403 Da when chelated with copper. The copper-chelated form (GHK-Cu) is the biologically active species; the unchelated tripeptide alone has substantially weaker biological effects in most assay systems, confirming that the copper coordination is essential to function rather than incidental.
The copper(II) ion binds to GHK through coordination with the nitrogen atoms of the glycine amine, the histidine imidazole ring, and the lysine amine, forming a stable square-planar complex. This arrangement allows GHK-Cu to function as a copper carrier — transporting copper to tissues that require it for enzymatic functions — while also generating its own direct biological signaling effects. Copper is an essential trace element required as a cofactor for over 30 human enzymes, including lysyl oxidase (which crosslinks collagen and elastin), cytochrome c oxidase (the terminal enzyme of the mitochondrial electron transport chain), ceruloplasmin (a ferroxidase), and superoxide dismutase 1 (SOD1, a key antioxidant enzyme).
In 2012, Dr. Pickart and colleagues published genomic analysis data suggesting that GHK-Cu influences the expression of more than 4,000 human genes — approximately one-fifth of the entire human genome — a finding with profound implications for understanding how a simple tripeptide can produce such wide-ranging biological effects. Research suggests GHK-Cu concentrations in plasma decline with age: young adult levels average around 200 ng/mL, declining to approximately 80 ng/mL by age 60. This age-associated decline has prompted interest in GHK-Cu as an intervention for age-related tissue deterioration. As of 2025, GHK-Cu has no FDA-approved pharmaceutical indication but is widely used as a cosmetic ingredient in topical formulations and is available as a research compound for subcutaneous injection studies.
One of GHK-Cu’s most well-characterized molecular mechanisms involves its activation of transforming growth factor beta (TGF-β) signaling in skin fibroblasts. TGF-β1 is the primary cytokine driver of collagen gene transcription in connective tissue; it binds the TGF-β receptor complex (TGFBR1 and TGFBR2), activating Smad2 and Smad3 phosphorylation, which then translocate to the nucleus and drive transcription of type I and type III procollagen genes. Research by Maquart and colleagues at the University of Reims demonstrated that GHK-Cu stimulates TGF-β1 secretion from human skin fibroblasts in culture, with downstream increases in type I procollagen synthesis measurable by radioimmunoassay and gene expression by Northern blot. The effect was concentration-dependent across a physiologically relevant range (1 to 100 nM).
Beyond collagen, TGF-β signaling activated by GHK-Cu also promotes proteoglycan synthesis (dermatan sulfate and heparan sulfate) and fibronectin production — additional extracellular matrix components critical to skin structural integrity. The copper ion’s role in this pathway appears to be both as a co-activator of the TGF-β pathway and as an essential cofactor for lysyl oxidase, the enzyme that crosslinks newly synthesized collagen fibrils into mature, mechanically strong collagen fibers. Without adequate copper delivery — which GHK-Cu provides — newly synthesized collagen would remain as soluble monomers rather than forming the crosslinked matrix needed for tensile strength. This dual role (signaling activation and enzymatic cofactor delivery) makes the copper chelate meaningfully more potent than either the peptide or copper alone.
Healthy tissue remodeling requires a carefully balanced system for breaking down old or damaged extracellular matrix components while simultaneously synthesizing new ones. This balance is regulated primarily by matrix metalloproteinases (MMPs) — a family of zinc-dependent endopeptidases — and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). In aged or chronically damaged skin, this balance is often tilted toward excessive matrix degradation, with elevated MMP activity and insufficient collagen synthesis leading to the thinning and loss of structural integrity characteristic of aged skin.
GHK-Cu exerts a bidirectional regulatory effect on this MMP/TIMP system. Research by Simeon and colleagues found that GHK-Cu increases expression of both MMP-2 (gelatinase A) and TIMP-2 in fibroblast cultures, suggesting it promotes the constructive matrix remodeling needed for scar reduction and tissue renewal while simultaneously preventing uncontrolled matrix degradation. This balanced action — promoting remodeling without tipping toward destruction — is mechanistically superior to simply inhibiting all MMPs (which would prevent the clearance of damaged matrix components that makes room for new tissue) or activating all MMPs (which would lead to accelerated matrix breakdown). The copper ion’s influence on zinc-dependent MMP activity is also likely relevant, as copper and zinc compete for metalloenzyme binding sites, and GHK-Cu-mediated copper delivery may modulate the local zinc availability on which MMP activity depends.
The scale of GHK-Cu’s genomic influence — suggested to encompass over 4,000 genes — represents the most striking and, in some ways, most mechanistically puzzling aspect of its biology. Pickart and colleagues used publicly available genomic databases (including the Broad Institute’s Connectivity Map) to identify genes whose expression patterns were influenced by GHK, finding activation of genes involved in collagen synthesis, antioxidant defense, DNA repair, proteasome activity, and anti-inflammatory signaling, alongside suppression of genes driving inflammation, oxidative stress, cancer progression, and cellular senescence.
Among the most clearly defined genomic effects is the upregulation of antioxidant genes. GHK-Cu has been shown to increase expression of superoxide dismutase 1 (SOD1), which dismutates superoxide radicals to hydrogen peroxide, and glutathione peroxidase (GPx), which reduces hydrogen peroxide and lipid peroxides. The mechanism by which a copper tripeptide activates such broad transcriptional programs is not fully resolved, but candidate mechanisms include: direct activation of the antioxidant response element (ARE) pathway through Nrf2 nuclear translocation, copper-mediated activation of copper-responsive transcription factors (MTF-1 in particular, which drives metallothionein and other copper-responsive genes), and modulation of chromatin accessibility through copper-dependent mechanisms involving lysine demethylases or other chromatin-remodeling enzymes that use copper as a cofactor. This remains an active area of investigation, and understanding the primary receptor or sensor through which GHK-Cu initiates its genomic effects is one of the central open questions in the field.
The skin rejuvenation evidence for GHK-Cu is among the deepest in cosmetic peptide research, spanning in vitro cell biology, ex vivo skin explant studies, and clinical trials with human subjects using topical formulations. Double-blind, placebo-controlled studies have demonstrated that topical GHK-Cu formulations (typically at 0.1 to 1.0% concentrations in cream or serum vehicles) produce measurable improvements in skin density (as assessed by ultrasound), elasticity (by cutometry), and surface texture after 12 to 24 weeks of use compared to vehicle controls. Punch biopsy histology from treated skin in some studies has shown increased dermal thickness, more organized collagen fiber architecture, and increased glycosaminoglycan content compared to untreated or placebo-treated control skin.
At the cellular level, GHK-Cu’s effects on fibroblast biology have been studied extensively in culture. Human dermal fibroblasts treated with GHK-Cu show increased proliferation, reduced apoptosis, enhanced collagen synthesis, and a gene expression profile more similar to younger cells than aged, untreated fibroblasts. Research by Finkley and colleagues examining GHK-Cu’s effects on the transcriptome of cultured dermal fibroblasts found that the peptide significantly shifted the expression of genes associated with aging toward a younger phenotype, supporting the genomic “resetting” hypothesis. Comparisons of GHK-Cu with other anti-aging peptide ingredients (such as Argireline/acetyl hexapeptide-3, which works by a different mechanism targeting neuromuscular junction-like signaling) show that GHK-Cu produces more robust changes in structural matrix components while the neuromuscular peptides focus on expression lines — complementary mechanisms often used in combination in advanced skin care formulations.
GHK-Cu’s wound healing effects have been documented across multiple animal models including excisional wound healing in rats and mice, diabetic wound healing in db/db mice (a standard model of impaired wound healing), and full-thickness burn wound healing. Across these models, GHK-Cu treatment — whether applied topically, incorporated into wound dressings, or injected subcutaneously at the wound margin — consistently accelerates wound closure, increases the density of new blood vessels in the healing tissue, and reduces scar formation compared to untreated controls.
The anti-scarring effect deserves particular attention. Excessive scar formation results from dysregulated fibroblast activity and overproduction of disorganized type I collagen during the proliferative healing phase. GHK-Cu’s balanced MMP/TIMP regulation appears to support the transition from the proliferative phase (collagen deposition) to the remodeling phase (organized collagen formation and scar maturation) more efficiently than untreated healing, reducing the hypercellular, disorganized collagen characteristic of hypertrophic scars. This effect has been observed in both acute surgical wound models and in studies examining the treatment of established scar tissue, where GHK-Cu application promotes remodeling of existing scar collagen toward a more organized, mechanically superior matrix. These wound healing properties are also why GHK-Cu has found application in post-procedure skincare protocols following laser resurfacing and chemical peels in cosmetic dermatology practice.
The most cited animal study for GHK-Cu’s hair growth effects was published in 1994 by Dr. Hideo Uno at the University of Wisconsin in collaboration with researchers studying androgens and hair follicle biology. Uno’s group, working with stump-tailed macaques — a primate model that develops androgenetic alopecia (male pattern baldness) closely paralleling the human condition — applied topical GHK-Cu formulations to defined scalp areas and measured hair follicle parameters including follicle size, shaft diameter, and growth rate using standardized photomicroscopy and follicular biopsy techniques.
The results showed that GHK-Cu treatment significantly increased follicular size in treated areas, with hair shaft diameters larger than both vehicle-treated control areas and untreated scalp. The miniaturized follicles characteristic of androgenetic alopecia showed partial reversal toward larger, more productive follicle morphology with GHK-Cu treatment. The mechanism proposed by Uno and subsequently explored by others centers on GHK-Cu’s promotion of follicular blood supply (via VEGF/angiogenic effects), stimulation of follicular stem cells in the bulge region, and potential anti-androgenic effects at the follicle level, though this last mechanism has not been definitively established. Subsequent studies using rodent models of hair regrowth confirmed that topical GHK-Cu promoted faster regrowth of shaved hair compared to controls and that formulation characteristics (concentration, vehicle, penetration enhancers) significantly affected efficacy. These findings have driven the inclusion of GHK-Cu as an active ingredient in numerous hair loss treatment formulations, though clinical trial data in humans with androgenetic alopecia specifically remains limited.
More recent research has explored GHK-Cu’s effects beyond skin and hair, particularly in the context of nerve regeneration and systemic aging biomarkers. In peripheral nerve injury models using rat sciatic nerve crush, GHK-Cu treatment (delivered systemically by subcutaneous injection in most studies) promoted faster functional nerve recovery, increased neurite outgrowth in dorsal root ganglion cultures, and reduced the fibrotic encapsulation that can impede nerve regeneration at injury sites. The proposed mechanisms involve GHK-Cu’s anti-inflammatory effects reducing the chronic inflammatory environment that impairs Schwann cell function and axonal regrowth, as well as direct neurotrophic properties including upregulation of BDNF and NGF expression in the injured nerve environment.
In the context of aging biomarkers, Pickart’s genomic analyses identified significant overlap between GHK-Cu’s gene expression signature and the gene expression changes associated with known longevity interventions in model organisms, including caloric restriction and mTOR inhibition. Specifically, GHK-Cu appeared to suppress gene networks associated with cellular senescence, oxidative phosphorylation uncoupling, and inflammatory NF-kB signaling — patterns associated with the aging phenotype at the molecular level. While these genomic observations are based on bioinformatic analysis rather than prospective aging studies, they have stimulated interest in GHK-Cu as a candidate molecule for systemic anti-aging research, particularly in the context of subcutaneous administration rather than purely topical use. Controlled long-term studies examining systemic aging biomarkers in response to GHK-Cu administration in animal models are an area of ongoing investigation.
Effective concentrations of GHK-Cu in cell culture studies typically range from 1 to 1,000 nM, with optimal collagen synthesis stimulation and fibroblast activity generally observed in the 1 to 100 nM range — remarkably low concentrations that reflect the peptide’s high potency at its molecular targets. Translating from in vitro concentrations to in vivo dosing is not straightforward, as distribution volume, degradation rate, and tissue penetration all affect the concentration ultimately delivered to target cells.
In animal wound healing studies, topical concentrations of 0.1 to 1.0% GHK-Cu (1 to 10 mg/mL) have been used in gel or cream formulations applied once or twice daily to wound sites. For subcutaneous injection in animal studies, doses of 1 to 10 mg/kg have been used in healing and nerve regeneration models. In the Uno macaque scalp study, the precise GHK-Cu concentration in the topical formulation was not the primary variable, as the study was comparative rather than dose-finding. For human research use, subcutaneous injections of GHK-Cu are typically studied at 1 to 3 mg per injection, though no formal human dose-response studies have been published. The peptide dosing calculator provides conversion utilities for research applications.
GHK-Cu has been meaningfully studied across three primary administration routes, each with distinct characteristics and applications.
Topical application is the most extensively researched route, driven by the cosmetic and wound care industries. GHK-Cu penetrates skin reasonably well compared to larger peptides, with its small size (340 Da) allowing passive diffusion through the stratum corneum, particularly when formulated in vehicles containing penetration enhancers like alcohol, propylene glycol, or liposomes. Topical delivery concentrates effects at the skin and underlying dermis — ideal for skin aging and wound care but not for systemic effects on tendons, nerves, or internal organs. The concentration at the epidermis and papillary dermis is high with topical application, but significant systemic bioavailability is not expected.
Subcutaneous injection provides systemic bioavailability, delivering GHK-Cu into the circulation where it can reach distant tissues. This route is used in animal studies examining systemic effects including wound healing (where injection site is distant from wound), nerve regeneration, and anti-aging biomarker studies. The small molecular weight of GHK-Cu means it would be rapidly cleared renally if not stabilized; some research formulations use slow-release excipients or liposomal encapsulation to extend the plasma concentration-time profile.
Intravenous administration has been used in some pharmacokinetic and early mechanism studies, providing immediate systemic exposure but requiring specialized settings and producing very short plasma half-lives for the free peptide. IV use is not a typical research administration route for GHK-Cu outside of controlled laboratory settings.
For topical applications in clinical studies, once to twice daily application for 12 to 24 weeks has been the typical protocol, consistent with the timeline for skin turnover and dermal remodeling to produce measurable structural changes. Skin collagen turnover has a half-life of several months, meaning short treatment durations are unlikely to produce large changes in dermal architecture even if cellular activity is enhanced. Most published cosmetic clinical trials examining GHK-Cu ran 12 to 24 weeks, with the most significant structural improvements emerging after 16 to 24 weeks.
For subcutaneous research injection protocols in animal studies, daily or every-other-day injections over 4 to 8 weeks have been used for wound healing and nerve regeneration studies. For systemic anti-aging applications, no standardized protocol exists in the published literature. Some researchers cycle GHK-Cu injection protocols in 4 to 8 week periods given the expectation that its genomic reset effect would produce relatively durable effects after a course of treatment, but this cycling approach is based on pharmacological reasoning rather than controlled cycling-versus-continuous-administration studies. Long-term continuous administration data in animals or humans is not available.
GHK-Cu for injectable research use is typically supplied as a lyophilized blue-green powder — the characteristic color results from the copper(II) chelate’s visible light absorption in the 600-700 nm range. Reconstitution uses bacteriostatic water or sterile saline, added gently to the vial and dissolved by gentle swirling. The solution typically retains the pale blue-green color characteristic of the copper complex. If a reconstituted solution becomes colorless, this may indicate loss of the copper chelate, either through precipitation or degradation, and quality should be reassessed.
Lyophilized GHK-Cu is stable at room temperature for limited periods (weeks to a few months) but is best stored at 4°C for short-term use or -20°C for longer storage. Reconstituted solution should be refrigerated and used within 30 days, protected from light and heat. The chelated copper is relatively stable under mild conditions, but extended exposure to extreme pH, oxidizing agents, or metal chelators (such as EDTA) can disrupt the copper-peptide complex. For topical formulations in cosmetic products, the stability of GHK-Cu at various pH levels is a significant formulation consideration — slightly acidic pH (4.5 to 6.5) generally preserves the copper complex better than alkaline conditions.
GHK-Cu has a favorable preclinical safety profile consistent with its natural origin as a fragment of human albumin. Acute toxicity studies in rodents have found no adverse effects at doses far exceeding those used in therapeutic or cosmetic applications. The peptide does not appear to accumulate to toxic levels in organs; copper homeostasis is tightly regulated in mammals, and GHK-Cu functions as a copper carrier rather than a copper accumulator, delivering copper where it is needed without producing systemic copper overload at therapeutic doses. Formal LD50 data is not widely published for GHK-Cu specifically, but the compound has been classified as non-toxic in standard Ames test assays and mammalian cell cytotoxicity testing at relevant concentrations. Long-term carcinogenicity studies have not been conducted, which is a gap in the formal safety data, though the compound’s observed genomic effects — including downregulation of cancer-associated gene networks — would not predict carcinogenic activity.
The primary safety consideration specific to GHK-Cu is its copper content. While the copper delivered per dose at research concentrations is well within the range of normal dietary copper intake (the RDA is 0.9 mg/day for adults), individuals with Wilson’s disease — a rare genetic disorder causing pathological copper accumulation due to defective ATP7B copper transporter function — should avoid copper-containing compounds including GHK-Cu. Individuals with copper sensitivity or allergy (uncommon but documented) may experience localized reactions to topical formulations.
Topical GHK-Cu in cosmetic formulations is generally very well tolerated, with the most common reported adverse effects being mild transient erythema or tingling in sensitive skin types, likely attributable to vehicle components rather than GHK-Cu itself. Subcutaneous injection site reactions (local swelling, erythema) are possible as with any injectable compound. There are no documented interactions between GHK-Cu and standard pharmaceutical medications in the published literature, though the compound’s broad genomic effects theoretically could influence drug metabolism pathways — a consideration warranting further investigation for any concurrent pharmaceutical use.
While GHK-Cu has a more extensive human evidence base than most research peptides (driven largely by its cosmetic industry application), several important limitations should be acknowledged. The cosmetic clinical trials demonstrating skin improvements used topical formulations, and findings from topical use cannot be directly extrapolated to systemic injection. The claim that GHK-Cu influences over 4,000 genes is based on bioinformatic analysis of genomic databases rather than controlled human transcriptomic studies, and the biological consequences of this broad gene expression influence have not been validated in human clinical endpoints. The hair growth data remains confined primarily to the macaque model and human anecdotal reports, without a published randomized controlled trial in human androgenetic alopecia. Subcutaneous injection studies with systemic endpoints (aging biomarkers, nerve regeneration, organ-level effects) are almost entirely from animal models, with the human clinical database essentially limited to skin and wound care. For questions about the current state of the evidence, the AI research coach can provide further context. This content is for research and informational purposes only.
The copper in GHK-Cu plays two essential roles. First, it is directly required for the biological activity of the peptide — the unchelated GHK tripeptide is substantially less active than GHK-Cu in most biological assays, indicating the copper is not just incidental but functionally necessary for the full range of GHK-Cu’s effects. Second, copper is required as a cofactor for numerous enzymes critical to tissue structure and function, particularly lysyl oxidase (which crosslinks collagen and elastin fibers) and superoxide dismutase 1 (a key antioxidant enzyme). By delivering bioavailable copper to tissues, GHK-Cu supports these enzymatic functions. The copper chelation also stabilizes the tripeptide against proteolytic degradation and helps regulate the rate at which copper is released to enzymatic targets — a controlled delivery function that free copper ions do not provide.
Yes, GHK-Cu is the copper peptide most commonly used in cosmetic formulations. It is also referred to by its INCI cosmetic ingredient name “Copper Tripeptide-1.” Different cosmetic brands may use slightly different formulations or concentrations, and the vehicle (cream, serum, oil) significantly affects skin penetration and therefore efficacy. Some products may use other copper-binding peptides or copper compounds that are not GHK-Cu specifically. When evaluating a cosmetic product, looking for “GHK-Cu,” “Copper Tripeptide-1,” or “Glycyl-L-Histidyl-L-Lysine copper” on the ingredient list confirms the presence of the specific compound covered in this article. Concentration matters: effective cosmetic concentrations in clinical studies have typically been 0.1 to 1.0%, though many commercial products do not disclose exact active ingredient concentrations.
Retinoids (including retinol and prescription tretinoin/retinoic acid) are the most evidence-backed topical anti-aging compounds, with decades of randomized controlled trial data demonstrating improvements in collagen content, wrinkle depth, skin texture, and hyperpigmentation. GHK-Cu’s evidence base, while substantial for a peptide, does not yet match the volume and strength of the retinoid literature. However, the two compounds work through complementary mechanisms: retinoids act primarily through nuclear retinoic acid receptors (RAR/RXR) to modulate transcription of collagen genes and matrix remodeling enzymes, while GHK-Cu acts through copper-dependent mechanisms including TGF-β signaling and genomic reprogramming. Many dermatologists and researchers view them as complementary rather than competing options. GHK-Cu is generally much better tolerated than retinoids (which commonly cause initial dryness, redness, and peeling) and is suitable for sensitive skin types that cannot tolerate retinoids.
Animal research, particularly the Uno 1994 macaque study, suggests that GHK-Cu applied topically to the scalp can increase hair follicle size and hair shaft diameter in primate models of androgenetic alopecia. This has driven the inclusion of GHK-Cu in numerous hair loss treatment products and serums. However, published randomized controlled trials specifically in human androgenetic alopecia are lacking, which means the evidence quality for this specific application is lower than for skin anti-aging. The mechanism — promotion of follicular blood supply, stimulation of follicular stem cells, and potential anti-androgenic activity — is biologically plausible and supported by the macaque data, but human response may differ. GHK-Cu is generally used in hair loss protocols as an adjunct to other evidence-based approaches rather than as a standalone treatment, and individual responses appear to vary considerably. Browse the peptide database for information on other hair-related research compounds.
Dr. Pickart’s bioinformatic analyses, using publicly available gene expression databases, found that GHK-Cu’s gene expression signature — the pattern of genes it upregulates and downregulates — significantly overlapped with gene expression changes associated with several known anti-aging conditions and interventions. Specifically, GHK-Cu appeared to reverse many of the gene expression changes associated with aging and cellular senescence, upregulating genes involved in tissue repair, antioxidant defense, proteasomal function, and differentiation while downregulating genes associated with inflammation, cancer progression, and cellular deterioration. The term “resetting” describes this apparent normalization of aged cell gene expression toward a more youthful pattern. Importantly, this is based on bioinformatic analysis of gene expression profiles rather than a controlled study directly measuring aging biomarkers in GHK-Cu-treated animals or humans over time, so while the genomic data is intriguing, it represents a hypothesis-generating observation rather than a proven anti-aging mechanism.
Based on published cosmetic clinical trial data, most participants in 12-to-24-week studies begin noticing subjective improvements in skin texture and hydration within the first 4 to 8 weeks of twice-daily topical application. Objective improvements measurable by clinical instruments — improved elasticity by cutometry, increased skin density by ultrasound, reduced wrinkle depth by profilometry — typically reach statistical significance at 12 weeks and continue improving through 24 weeks of treatment. The pace of improvement reflects the biology of skin remodeling: dermal collagen synthesis and reorganization is a slow process governed by fibroblast activity and collagen fiber maturation timelines. Very visible improvements in deep structural wrinkles require longer periods and are typically less dramatic with topical GHK-Cu alone than with procedures like laser resurfacing; however, GHK-Cu is often used in post-procedure recovery protocols where it accelerates the healing and remodeling phases.
For systemic effects — those affecting tissues beyond the skin, such as tendons, joints, nerves, or internal organs — injectable GHK-Cu would logically provide superior bioavailability compared to topical application, which has limited transdermal penetration into systemic circulation. The animal studies demonstrating wound healing, nerve regeneration, and the broader biological effects described in this article used either injection or direct wound application rather than topical application to skin. However, no human comparative trial has directly assessed topical versus injectable GHK-Cu for systemic endpoints. For purely skin-focused applications, topical remains the most practical and evidence-supported route, delivering active concentrations directly to the dermis. For systemic anti-aging research applications, subcutaneous injection is the route most consistent with animal study protocols, but the human clinical evidence base for systemic injectable GHK-Cu is considerably thinner than for topical use.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.